Kainate receptors: Pharmacology, function and therapeutic potential

Neuropharmacology

Volumn 56, Issue 1, 2009, Pages 90-113

  Jane, David E ^a   Lodge, David ^a   Collingridge, Graham L ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Agonists; Antagonists; Kainate receptors; LTP; Synaptic plasticity; Therapeutic potential

Indexed keywords

2 [5 (4 DIMETHYLSULFAMOYLPHENYL) 6,7,8,9 TETRAHYDRO 8 METHYL 2 OXO 1H PYRROLO[3,2 H]ISOQUINOLIN 3 YLIMINOXY] 4 HYDROXYBUTYRIC ACID; 4 [3 (2 NAPHTHYL)ALLYL]GLUTAMIC ACID; 4 METHYLGLUTAMIC ACID; 5 CHLORO 7 TRIFLUOROMETHYL 2,3 QUINOXALINEDIONE; 5 IODOWILLARDIINE; 6 (4 CARBOXYBENZYL) 1,2,3,4,4A,5,6,7,8,8A DECAHYDRO 3 ISOQUINOLINECARBOXYLIC ACID; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 6,7,8,9 TETRAHYDRO 5 NITROBENZ[G]INDOLE 2,3 DIONE 3 OXIME; 8 DEOXYNEODYSIHERBAINE; 9 DEOXYNEODYSIHERBAINE; ALPHA AMINO 5 TERT BUTYL 3 HYDROXY 4 ISOXAZOLEPROPIONIC ACID; AUTORECEPTOR; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DOMOIC ACID; DYSIHERBAINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; KAINIC ACID; KAINIC ACID RECEPTOR; KAINIC ACID RECEPTOR AGONIST; KAINIC ACID RECEPTOR ANTAGONIST; KYNURENIC ACID; LU 115455; LU 136541; LU 97175; LY 377770; LY 466195; NEODYSIHERBAINE; UBP 282; UBP 296; UBP 304; UBP 310; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTICONVULSANT ACTIVITY; DEGENERATIVE DISEASE; DRUG BINDING SITE; DRUG INDICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; EPILEPSY; HUMAN; LEARNING; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MEMORY; MENTAL DISEASE; MIGRAINE; NERVE CELL PLASTICITY; NEUROPHARMACOLOGY; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PAIN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SYNAPTIC TRANSMISSION; TOOTH PAIN;

ANIMALS; HUMANS; KAINIC ACID; MODELS, BIOLOGICAL; NERVOUS SYSTEM DISEASES; RECEPTORS, KAINIC ACID;

EID: 58049096661     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.08.023     Document Type: Review

References (207)

1. 2+ signal transduction. Journal of Biological Chemistry 267 (1992) 13361-13368
2. Agrawal S.G., and Evans R.H. The primary afferent depolarizing action of kainate in the rat. British Journal of Pharmacology 87 (1986) 345-355
3. Alberdi E., Sánchez-Gómez M.V., Torre I., Domercq M., Pérez-Samartín A., Pérez-Cerdá F., and Matute C. Activation of kainate receptors sensitizes oligodendrocytes to complement attack. Journal of Neuroscience 26 (2006) 3220-3228
4. Ali A.B., Rossier J., Staiger J.F., and Audinat E. Kainate receptors regulate unitary IPSCs elicited in pyramidal cells by fast-spiking interneurons in the neocortex. Journal of Neuroscience 21 (2001) 2992-2999
5. Alt A., Weiss B., Ogden A.M., Knauss J.L., Oler J., Ho K., Large T.H., and Bleakman D. Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro. Neuropharmacology 46 (2004) 793-806
6. K5 kainate receptor mechanism. Neuropharmacology 52 (2007) 1482-1487
7. Aramori I., and Nakanishi S. Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluR1, in transfected CHO cells. Neuron 8 (1992) 757-765
8. Armstrong N., Sun Y., Chen G.-Q., and Gouaux E. Structure of a glutamate-receptor ligand-binding core in complex with kainate. Nature 395 (1998) 913-917
9. Bahn S., Volk B., and Wisden W. Kainate receptor gene expression in the developing rat brain. Journal of Neuroscience 14 (1994) 5525-5547
10. Bahring R., and Mayer M.L. An analysis of philanthotoxin block for recombinant rat GluR6(Q) glutamate receptor channels. Journal of Physiology 509 (1998) 635-650
11. Baker S.R., Bleakman D., Ezquerra J., Ballyk B.A., Deverill M., Ho K., Kamboj R.K., Collado I., Domínguez C., Escribano A., Mateo A.I., Pedregal C., and Rubio A. 4-Alkylidenyl glutamic acids, potent and selective GluR5 antagonists. Bioorganic & Medicinal Chemistry Letters 10 (2000) 1807-1810
12. Barbon A., Fumagalli F., LaVia L., Caracciolo L., Racagni G., Riva M.A., and Barlati S. Chronic phencyclidine administration reduces the expression and editing of specific glutamate receptors in rat prefrontal cortex. Experimental Neurology 208 (2007) 54-62
13. Barker G.R.I., Warburton E.C., Koder T., Aggleton J.P., Bashir Z.I., Auberson Y., Jane D.E., and Brown M.W. Kainate and NMDA glutamate receptor antagonism impairs recognition memory at different times. Journal of Neuroscience 26 (2006) 3561-3566
14. Begni S., Popoli M., Moraschi S., Bignotti S., Tura G.B., and Gennerelli M. Association between the ionotropic glutamate receptor kainate 3 (GRIK3) ser310ala polymorphism and schizophrenia. Molecular Psychiatry 7 (2002) 416-418
15. Ben-Ari Y., and Cossart R. Kainate, a double agent that generates seizures: two decades of progress. Trends in Neurosciences 23 (2000) 580-587
16. Beneyto M., Kristiansen L.V., Oni-Orisan A., McCullumsmith R.E., and Meador-Woodruff J.H. Abnormal glutamate receptor in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 32 (2007) 1888-1902
17. Bettler B., Boulter J., Hermans-Borgmeyer I., O'Shea-Greenfield A., Deneris E.S., Moll C., Borgmeyer U., Hollman M., and Heinemann S. Cloning of a novel glutamate receptor subunit, GluR5: expression in the central nervous system during development. Neuron 5 (1990) 583-595
18. Bettler B., Egebjerg J., Sharma G., Pecht G., Hermansborgmeyer I., Moll C., Stevens C.F., and Heinemann S. Cloning of a putative glutamate receptor - a low affinity kainate-binding subunit. Neuron 8 (1992) 257-265
19. Bettler B., and Mulle C. Neurotransmitter receptors. 2. AMPA and kainate receptors. Neuropharmacology 34 (1995) 123-139
20. Binns K.E., Turner J.P., and Salt T.E. Kainate receptor (GluR5)-mediated disinhibition of responses in rat ventrobasal thalamus allows a novel sensory processing mechanism. Journal of Physiology 551 (2003) 525-537
21. Birch P.J., Grossman C.J., and Hayes A.G. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. European Journal of Pharmacology 154 (1988) 85-87
22. Birch P.J., Grossman C.J., and Hayes A.G. 6,7-Dinitro-quinoxaline- 2,3-dion and 6-nitro,7-cyano-quinoxaline-2,3-dion antagonise responses to NMDA in the rat spinal cord via an action at the strychnine-insensitive glycine receptor. European Journal of Pharmacology 156 (1988) 177-180
23. Biscoe T.J., Evans R.H., Headley P.M., Martin M., and Watkins J.C. Domoic and quisqualic acids as potent excitants of frog and rat spinal neurones. Nature 255 (1975) 166-167
24. Blaschke M., Keller B.U., Rivosecchi R., Hollmann M., Heinemann S., and Konnerth A. A single amino acid determines the subunit-specific spider toxin block of α-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor channels. Proceedings of the National Academy of Sciences of the United States of America 90 (1993) 6528-6532
25. Bleakman D., Gates M.R., Ogden A.M., and Mackowiak M. Kainate receptor agonists, antagonists, and allosteric modulators. Current Pharmaceutical Design 8 (2002) 873-885
26. Bleakman D., and Lodge D. Neuropharmacology of AMPA and kainate receptors. Neuropharmacology 37 (1998) 1187-1204
27. Bleakman D., Schoepp D.D., Ballyk B., Bufton H., Sharpe E.F., Thomas K., Ornstein P.L., and Kamboj R.K. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3 carboxylic acid. Molecular Pharmacology 49 (1996) 581-585
28. Bleisch T.J., Ornstein P.L., Allen N.K., Wright R.A., Lodge D., and Schoepp D.D. Structure-activity studies of aryl-spaced decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. Bioorganic & Medicinal Chemistry Letters 7 (1997) 1161-1166
29. Bortolotto Z.A., Clarke V.R.J., Delany C.M., Parry M.C., Smolders I., Vignes M., Ho K.H., Miu P., Brinton B.T., Fantaske R., Ogden A., Gates M., Ornstein P.L., Lodge D., Bleakman D., and Collingridge G.L. Kainate receptors are involved in synaptic plasticity. Nature 402 (1999) 297-301
30. Bortolotto Z.A., Lauri S., Isaac J.T., and Collingridge G.L. Kainate receptors and the induction of mossy fibre long-term potentiation. Philosophical Transactions of the Royal Society 358 (2003) 657
31. Bowie D. External anions and cations distinguish between AMPA and kainate receptor gating mechanisms. Journal of Physiology (London) 539 (2002) 725-733
32. Bowie D., Garcia E.P., Marshall J., Traynellis S.F., and Lange G.D. Allosteric regulation and spatial distribution of kainate receptors bound to ancillary proteins. Journal of Physiology (London) 547 (2003) 373-385
33. Braga M.F., Aroniadou-Anderjaska V., Xie J., and Li H. Bidirectional modulation of GABA release by presynaptic glutamate receptor 5 kainate receptors in the basolateral amygdala. Journal of Neuroscience 23 (2003) 442-452
34. Brauner-Osborne H., Egebjerg J., Nielsen E.O., Madsen U., and Krogsgaard-Larsen P. Ligands for glutamate receptors: design and therapeutic prospects. Journal of Medicinal Chemistry 43 (2000) 2609-2645
35. Brehm L., Greenwood J.R., Hansen K.B., Nielsen B., Egebjerg J., Stensbøl T.B., Bräuner-Osborne H., Sløk F.K., Kronborg T.T.A., and Krogsgaard-Larsen P. (S)-2-amino-3-(3-hydroxy-7,8-dihydro-6H-cyclohepta[d]isoxazol-4-yl)propi onic acid, a potent and selective agonist at the GluR5 subtype of ionotropic glutamate receptors. Synthesis, modelling and molecular pharmacology. Journal of Medicinal Chemistry 46 (2003) 1350-1358
36. K6 at hippocampal mossy fiber synapses. Journal of Neuroscience 24 (2004) 10093-10098
37. K5-containing receptors in kainate-driven hippocampal gamma band oscillations. Neuropharmacology 50 (2006) 47-56
38. Bufler J., Cordes A., Heineke W., Dengler R., and Krampfl K. Pentobarbital and brilliant green modulate the current response of recombinant rat kainate-type GluR6 receptor channels differentially. Neuroscience Letters 312 (2001) 91-94
39. Bullock R., Graham D.I., Swanson S., and McCulloch J. Neurprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat. Journal of Cerebral Blood Flow and Metabolism 14 (1994) 466-471
40. Bureau I., Bischoff S., Heinemann S.F., and Mulle C. Kainate receptor-mediated responses in the CA1 field of wild-type and GluR6-deficient mice. Journal of Neuroscience 19 (1999) 635-663
41. Campbell S.L., Mathew S.S., and Hablitz J.J. Pre- and postsynaptic effects of kainate on layer II/III pyramidal cells in rat neocortex. Neuropharmacology 53 (2007) 37-47
42. Castillo P.E., Malenka R.C., and Nicoll R.A. Kainate receptors mediate a slow postsynaptic current in hippocampal CA3 neurons. Nature 388 (1997) 182-186
43. Chittajallu R., Braithwaite S.P., Clarke V.R., and Henley J.M. Kainate receptors: subunits, synaptic localization and function. Trends in Pharmacological Sciences 20 (1999) 26-35
44. Chittajallu R., Vignes M., Dev K.K., Barnes J.M., Collingridge G.L., and Henley J.M. Regulation of glutamate release by presynaptic kainate receptors in the hippocampus. Nature 379 (1996) 78-81
45. Christensen J.K., Paternain A.V., Selak S., Ahring P.K., and Lerma J. A mosaic of functional kainate receptors in hippocampal interneurons. Journal of Neuroscience 24 (2004) 8986-8993
46. K5 receptors. Journal of Pharmacology and Experimental Therapeutics 309 (2004) 1003-1010
47. Clarke V.R.J., Ballyk B.A., Hoo K.H., Mandelzys A., Pellizzari A., Bath C.P., Thomas J., Sharpe E.F., Davies C.H., Ornstein P.L., Schoepp D.D., Kamboj R.K., Collingridge G.L., Lodge D., and Bleakman D. A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature 389 (1997) 599-603
48. Collingridge G.L., Olsen R.W., Peters J., and Spedding M. A nomenclature for ligand-gated ion channels. Neuropharmacology 56 (2009) 2-5
49. Contractor A., Swanson G., and Heinemann S.F. Kainate receptors are involved in short- and long-term plasticity at mossy fiber synapses in the hippocampus. Neuron 29 (2001) 209-216
50. Cossart R., Esclapez M., Hirsch J.C., Bernard C., and Ben-Ari Y. GluR5 kainate receptor activation in interneurons increases tonic inhibition of pyramidal cells. Nature Neuroscience 1 (1998) 470-478
51. Cui C., and Mayer M.L. Heteromeric kainate receptors formed by the coassembly of GluR5, GluR6 and GluR7. Journal of Neuroscience 19 (1999) 8281-8291
52. Cunningham M.O., Pervouchine D.D., Racca C., Kopell N.J., Davies C.H., Jones R.S., Traub R.D., and Whittington M.A. Neuronal metabolism governs cortical network response state. Proceedings of the National Academy of Sciences of the United States of America 103 (2006) 5597-5601
53. Dargan S.L., Clarke V.R.J., Alushin G.M., Sherwood J.L., Nistico R., Bortolotto Z.A., Doherty A., Lodge D., Mayer M.L., Fitzjohn S.M., Jane D.E., and Collingridge G.L. ACET is a highly potent and specific kainate receptor antagonist: characterisation and effects on hippocampal mossy fibre function. Neuropharmacology 56 (2009) 121-130
54. Davies J., Jones A.W., Sheardown M.J., Smith D.A.S., and Watkins J.C. Phosphono dipeptides and piperazine derivatives as antagonists of amino acid-induced and synaptic excitation in mammalian and amphibian spinal cord. Neuroscience Letters 52 (1984) 79-84
55. Davies J., and Watkins J.C. Depressant actions of γ-d-glutamylaminomethyl sulfonate (GAMS) on amino acid-induced and synaptic excitation in the cat spinal cord. Brain Research 327 (1985) 113-120
56. Delaney A.J., and Jahr C.E. Kainate receptors differentially regulate release at two parallel fiber synapses. Neuron 36 (2002) 475-482
57. Dildy-Mayfield J.E., Eger II E.I., and Harris R.A. Anesthetics produce subunit-selective actions on glutamate receptors. Journal of Pharmacology and Experimental Therapeutics 276 (1996) 1058-1065
58. K5 kainate receptor antagonists. Journal of Medicinal Chemistry 50 (2007) 1558-1570
59. 3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists. Journal of Medicinal Chemistry 49 (2006) 2579-2592
60. Dolman N.P., Troop H.M., More J.C.A., Alt A.J., Ogden A.M., Jones S., Morley R.M., Roberts P.J., Bleakman D., Collingridge G.L., and Jane D.E. Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors. Journal of Medicinal Chemistry 48 (2005) 7867-7881
61. Dominguez A., Iyengar S., Shannon H.E., Bleakman D., Alt A., Arnold B.M., Bell M.G., Bleisch T.J., Buckmaster J.L., Castano A.M., Del Prado M., Escribano A., Filla S.A., Ho K.H., Hudziak K.J., Jones C.K., Martinez-Perez J.A., Mateo A., Mathes B.M., Mattiuz E.L., Ogden A.M.L., Simmons R.M., Stack D.R., Stratford R.E., Winter M.A., Wu Z., and Ornstein P.L. Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain. Journal of Medicinal Chemistry 48 (2005) 4200-4203
62. Donevan S.D., Beg A., Gunther J.M., and Twyman R.E. The methylglutamate, SYM 2081, is a potent and highly selective agonist at kainate receptors. Journal of Pharmacology and Experimental Therapeutics 285 (1998) 539-545
63. Evans R.H., Evans S.J., Pook P.C., and Sunter D.C. A comparison of excitatory amino-acid antagonists acting at primary afferent C-fibres and motoneurones of the rat isolated spinal-cord of the rat. British Journal of Pharmacology 91 (1987) 531-537
64. Everts I., Petroski R., Kizelsztein P., Teichberg V.I., Henemann S.F., and Hollman M. Lectin-induced inhibition of desensitization of the kainate receptor GluR6 depends on the activation state and can be mediated by a single native ectopic N-linked carbohydrate side chain. Journal of Neuroscience 19 (1999) 916-927
65. Filla S.A., Winter M.A., Johnson K.W., Bleakman D., Bell M.G., Bleisch T.J., Castaño A.M., Clemens-Smith A., del Prado M., Dieckman D.K., Dominguez E., Escribano A., Hoo K.H., Hudziak K.J., Katofiasc M.A., Martinez-Perez J.A., Mateo A., Mathes B.M., Mattiuz E.L., Ogden A.M.L., Phebus L.A., Stack D.R., Stratford R.E., and Ornstein P.L. Ethyl (3S,4aR,6S8aR)-6-(4-ethoxycarbonylimidazol-1-ylmethyl)decahydroisoquinol ine-3-carboxylic ester: a prodrug of a GluR5 KA receptor antagonist active in two animal models of acute migraine. Journal of Medicinal Chemistry 45 (2002) 4383-4386
66. Fletcher E.J., and Lodge D. New developments in the molecular pharmacology of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate and kainate receptors. Pharmacology and Therapeutics 70 (1996) 65-89
67. Fletcher E.J., Martin D., Aram J.A., Lodge D., and Honoré T. Quinoxalinediones selectively block quisqualate and kainate receptors and synaptic events in rat neocortex and hippocampus and frog spinal cord in vitro. British Journal of Pharmacology 95 (1988) 585-597
68. Frerking M., Malenka R.C., and Nicoll R.A. Synaptic activation of kainate receptors on hippocampal interneurons. Nature Neuroscience 1 (1998) 479-486
69. Frerking M., Schmitz D., Zhou Q., Johansen J., and Nicoll R.A. Kainate receptors depress excitatory synaptic transmission at CA3 → CA1 synapses in the hippocampus via a direct presynaptic action. Journal of Neuroscience 21 (2001) 2958-2966
70. Fukushima T., Shinghai R., Ogurusu T., and Ichinose M. Inhibition of willardiine-induced currents through rat GluR6/KA-2 kainate receptor channels by zinc and other divalent cations. Neuroscience Letters 349 (2003) 107-110
71. Gallyas F., Ball S.M., and Molnar E. Assembly and cell surface expression of KA-2 subunit-containing kainate receptors. Journal of Neurochemistry 86 (2003) 1414-1427
72. Ganong A.H., Jones A.W., Watkins J.C., and Cotman C.W. Parallel antagonism of synaptic transmission and kainate and quisqualate responses in the hippocampus by piperazine-2,3-dicarboxylic acid analogs. Journal of Neuroscience 6 (1986) 930-937
73. Ganong A.H., Lanthorn T.H., and Cotman C.W. Kynurenic acid inhibits synaptic and acidic amino acid-induced responses in the rat hippocampus and spinal cord. Brain Research 273 (1983) 170-174
74. Gill R., and Lodge D. The neuroprotective effects of the decahydroisoquinoline, LY 215490; a novel AMPA antagonist in focal ischaemia. Neuropharmacology 33 (1994) 1529-1536
75. Gilron I., Max M.B., Lee G., Booher S.L., Sang C.N., Chappell A.S., and Dionne R.A. Effects of the 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain. Clinical Pharmacology & Therapeutics 68 (2000) 320-327
76. Guo W., Zuo S., Tal M., and Ren K. Activation of spinal kainate receptors after inflammation; behavioral hyperalgesia and subunit gene expression. European Journal of Pharmacology 452 (2002) 309-318
77. Hald H., Naur P., Pickering D.S., Sprogøe D., Madsen U., Timmermann D.B., Ahring P.K., Liljefors T., Schousboe A., Egebjerg J., Gajhede M., and Kastrup J.S. Partial agonism and antagonism of the ionotropic glutamate receptor iGLuR5 - structures of the ligand-binding core in complex with domoic acid and 2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acid. Journal of Biological Chemistry 282 (2007) 25726-25736
78. Hirbec H., Francis J.C., Lauri S.E., Braithwaite S.P., Coussen F., Mulle C., Dev K.K., Couthino V., Meyer G., Isaac J.T., Collingridge G.L., and Henley J.M. Rapid and differential regulation of AMPA and kainate receptors at hippocampal mossy fibre synapses by PICK1 and GRIP. Neuron 37 (2003) 625-638
79. Hogner A., Greenwood J.R., Liljefors T., Lunn M.L., Egebjerg J., Larsen I.K., Gouaux E., and Kastrup J.S. Competitive antagonism of AMPA receptors by ligands of different classes: crystal structure of ATPO bound to the GluR2 ligand-binding core, in comparison with DNQX. Journal of Medicinal Chemistry 46 (2003) 214-221
80. Hollmann M., and Heinemann S. Cloned glutamate receptors. Annual Review Neuroscience 17 (1994) 31-108
81. Huettner J.E. Glutamate receptor channels in rat DRG neurons: activation by kainate and quisqualate and blockade of desensitization by Con A. Neuron 5 (1990) 255-266
82. Huettner J.E., Stack E., and Wilding T.J. Antagonism of neuronal kainate receptors by lanthanum and gadolinium. Neuropharmacology 37 (1998) 1239-1247
83. Huxter J.R., Zinyuk L.E., Roloff E.v.L., Clarke V.R.J., Dolman N.P., More J.C.A., Jane D.E., Collingridge G.L., and Muller R.U. Blockade of kainate receptors reduces the frequency of hippocampal theta oscillations. Journal of Neuroscience 27 (2007) 2212-2223
84. Jane D.E., Hoo K., Kamboj R., Deverill M., Bleakman D., and Mandelzys A. Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes. Journal of Medicinal Chemistry 40 (1997) 3645-3650
85. Jane D.E., Pook P.C.-K., Sunter D.C., Udvarhelyi P.M., and Watkins J.C. New willardiine analogues with potent, stereoselective actions on mammalian spinal neurones. British Journal of Pharmacology 104 (1991) 333P
86. Jiang H.X., Guan Q.H., Pei D.S., and Zhang D.Y. Functional cooperation between KA2 and GluR6 subunits is involved in the ischemic brain injury. Journal of Neuroscience Research 85 (2007) 2960-2970
87. Jin R., Banke T.G., Mayer M.L., Traynelis S.F., and Gouaux E. Structural basis for partial agonist action at ionotropic glutamate receptors. Nature Neuroscience 6 (2003) 803-810
88. K5 (GluR5) ionotropic glutamate receptor antagonists in the capsaicin and carrageenan models in rats. Journal of Pharmacology and Experimental Therapeutics 319 (2006) 396-404
89. Jones K.A., Wilding T.J., Huettner J.E., and Costa A.M. Desensitization of kainate receptors by kainate, glutamate and diastereomers of 4-methylglutamate. Neuropharmacology 36 (1997) 853-863
90. Kaminski R.M., Banerjee M., and Rogawski M.A. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 46 (2004) 1097-1104
91. 2+ influx and EPSP in area CA1 of the rat hippocampus. Journal of Physiology 509 (1998) 833-845
92. Kasper C., Pickering D.S., Mirza O., Olsen L., Kristensen A.S., Greenwood J.R., Liljefors T., Schousboe A., Wtjen F., Gajhede M., Sigurskjold B.W., and Kastrup J.S. The structure of a mixed GluR2 ligand-binding core dimer in complex with (S)-glutamate and the antagonist (S)-NS1209. Journal of Molecular Biology 357 (2006) 1184-1201
93. Kerchner G.A., Wilding T.J., Huettner J.E., and Zhuo M. Kainate receptor subunits underlying presynaptic regulation of transmitter release in the dorsal horn. Journal of Neuroscience 22 (2002) 8010-8017
94. Kerchner G.A., Wilding T.J., Li P., Zhuo M., and Huettner J.E. Presynaptic kainate receptors regulate spinal sensory transmission. Journal of Neuroscience 21 (2001) 59-66
95. Kew J.N.C., and Kemp J.A. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 179 (2005) 4-29
96. Khalilov I., Hirsch J., Cossart R., and Ben-Ari Y. Paradoxical anti-epileptic effects of a GluR5 agonist of kainate receptors. Journal of Neurophysiology 88 (2002) 523-527
97. Kidd F.L., Coumis U., Collingridge G.L., Crabtree J.W., and Isaac J.T. A presynaptic kainate receptor is involved in regulating the dynamic properties of thalamocortical synapses during development. Neuron 34 (2002) 635-646
98. Kidd F.L., and Isaac J.T. Developmental and activity-dependent regulation of kainate receptors at thalamocortical synapses. Nature 400 (1999) 569-573
99. Kiskin N.I., Krishtal O.A., and Tsyndrenko A.Y. Excitatory amino acid receptors in hippocampal neurons: kainate fails to desensitize them. Neuroscience Letters 63 (1986) 225-230
100. Konno K., Shirahama H., and Matsumoto T. Isolation and structure of acromelic acid A and B. New kainoids of Clitocybe acromelaga. Tetrahedron Letters 24 (1983) 939-942
101. Lash L.L., Sanders J.M., Akiyama N., Shoji M., Postila P., Pentikainen O.T., Sasaki M., Sakai R., and Swanson G.T. Novel analogs and stereoisomers of the marine toxin neodysiherbaine with specificity for kainate receptors. Journal of Pharmacology and Experimental Therapeutics 324 (2008) 484-496
102. Lauri S.E., Bortolotto Z.A., Bleakman D., Ornstein P.L., Lodge D., Isaac J.T., and Collingridge G.L. A critical role of a facilitatory presynaptic kainate receptor in mossy fiber LTP. Neuron 32 (2001) 697-709
103. 2+ stores in kainate receptor-dependent synaptic facilitation and LTP at mossy fiber synapses in the hippocampus. Neuron 39 (2003) 327-341
104. Lauri S.E., Segerstrale M., Vesikansa A., Maingret F., Mulle C., Collingridge G.L., Isaac J.T., and Taira T. Endogenous activation of kainate receptors regulates glutamate release and network activity in the developing hippocampus. Journal of Neuroscience 25 (2005) 4473-4484
105. Lauri S.E., Vesikansa A., Segerstrale M., Collingridge G.L., Isaac J.T., and Taira T. Functional maturation of CA1 synapses involves activity-dependent loss of tonic kainate receptor-mediated inhibition of glutamate release. Neuron 50 (2006) 415-429
106. Leeson P.D., Baker R., Carling R.W., Curtis N.R., Moore K.W., Williams B.J., Foster A.C., Donald A.E., Kemp J.A., and Marshall G.R. Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-d-aspartate receptor. Journal of Medicinal Chemistry 34 (1991) 1243-1252
107. Lerma J. Roles and rules of kainate receptors in synaptic transmission. Nature Reviews Neuroscience 4 (2003) 481-495
108. Lerma J. Kainate receptor physiology. Current Opinion in Pharmacology 6 (2006) 89-97
109. Lerma J., Paternain A.V., Rodriguez-Moreno A., and Lopez-Garcia J.C. Molecular physiology of kainate receptors. Physiological Reviews 81 (2001) 971-998
110. Li H., Chen A., Xing G., Wei M.L., and Rogawski M.A. Kainate receptor-mediated heterosynaptic facilitation in the amygdala. Nature Neuroscience 4 (2001) 612-620
111. Li H., and Rogawski M.A. GluR5 kainate receptor mediated synaptic transmission in rat basolateral amygdala in vitro. Neuropharmacology 37 (1998) 1279-1286
112. Lodge D. The history of the pharmacology and cloning of ionotropic glutamate receptors and the development of idiosyncratic nomenclature. Neuropharmacology 56 (2009) 6-21
113. Löscher W., Lehmann H., Behl B., Seemann D., Teschendorf H.J., Hofmann H.P., Lubisch W., Höger T., Lemaire H.-G., and Groß G. A new pyrrolyl-quinoxalinedione series of non-NMDA glutamate receptor antagonists: pharmacological characterization and comparison with NBQX and valproate in the kindling model of epilepsy. European Journal of Neuroscience 11 (1999) 250-262
114. Lubisch W., Behl B., Henn C., Hofmann H.P., Reeb J., Regner F., and Vierling M. Pyrrolylquinoxalinediones carrying a piperazine residue represent highly potent and selective ligands to the homomeric kainate receptor GluR5. Bioorganic & Medicinal Chemistry Letters 12 (2002) 2113-2116
115. Lutfy K., Woodward R.M., Keana J.F.W., and Weber E. Inhibition of clonic seizure-like excitatory effects induced by intrathecal morphine using 2 NMDA receptor antagonists - MK-801 and ACEA-1011. European Journal of Pharmacology 252 (1994) 261-266
116. Mascias P., Scheede M., Bloms-Funke P., and Chizh B. Modulation of spinal nociception by GluR5 kainate receptor ligands in acute and hyperalgesic states and the role of gabaergic mechanisms. Neuropharmacology 43 (2002) 327-339
117. Mathew S.S., and Hablitz J.J. Calcium release via activation of presynaptic IP3 receptors contributes to kainate-induced IPSC facilitation in rat neocortex. Neuropharmacology 55 (2008) 106-116
118. Mayer M.L. Crystal structures of the GluR5 and GluR6 ligand binding cores: molecular mechanisms underlying kainate receptor selectivity. Neuron 45 (2005) 539-552
119. Mayer M.L. Glutamate receptors at atomic resolution. Nature 440 (2006) 456-462
120. Mayer M.L., Ghosal A., Dolman N.P., and Jane D.E. Crystal structures of the kainate receptor GluR5 ligand binding core dimer complex with novel selective antagonists. Journal of Neuroscience 26 (2006) 2852-2861
121. Minami K., Wick M.J., Stern-Bach Y., Dildy-Mayfield J.E., Brozowski S.J., Gonzales E.L., Trudell J.R., and Harris R.A. Sites of volatile anesthetic action on kainate (glutamate receptor 6) receptors. Journal of Biological Chemistry 273 (1998) 8248-8255
122. Møller E.H., Egebjerg J., Brehm L., Stensbøl T.B., Johansen T.N., Madsen U., and Krogsgaard-Larsen P. Resolution, absolute stereochemistry, and enantiopharmacology of the GluR1-4 and GluR5 antagonist 2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acid. Chirality 11 (1999) 752-759
123. 3H]kainic acid binding sites in rat CNS as determined by autoradiography. Brain Research 252 (1982) 91-100
124. More J.C.A., Nitisco R., Dolman N.P., Clarke V.R.J., Alt A.J., Ogden A.M., Buelens F.P., Troop H.M., Kelland E.E., Pilato F., Bleakman D., Bortolotto Z.A., Collingridge G.L., and Jane D.E. Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology 47 (2004) 46-64
125. More J.C.A., Troop H.M., Dolman N.P., and Jane D.E. Structural requirements for novel willardiine derivatives acting as AMPA and kainate receptor antagonists. British Journal of Pharmacology 138 (2003) 1093-1100
126. More J.C.A., Troop H.M., and Jane D.E. The novel antagonist 3-CBW discriminates between kainate receptors expressed on neonatal rat motoneurones and those on dorsal root C-fibres. British Journal of Pharmacology 137 (2002) 1125-1133
127. Naur P., Vestergaard B., Skov L.K., Egebjerg J., Gajhede M., and Kastrup J.S. Crystal structure of the kainate receptor GluR5 ligand-binding core in complex with (S)-glutamate. FEBS Letters 579 (2005) 1154-1160
128. Nicoll R.A., Mellor J., Frerking M., and Schmitz D. Kainate receptors and synaptic plasticity. Nature 406 (2000) 957
129. Nielsen E.Ø., Varming T., Mathiesen C., Jensen L.H., Møller A., Gouliaev A.H., Wätjen F., and Drejer J. SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity. Journal of Pharmacology and Experimental Therapeutics 289 (1999) 1492-1501
130. Nitta I., Watase H., and Tomiie Y. Structure of kainic acid and its isomer, allokainic acid. Nature 181 (1958) 761-762
131. O'Neill M.J., Bogaert L., Hicks C.A., Bond A., Ward M.A., Ebinger G., Ornstein P.L., Michotte Y., and Lodge D. LY377770, a novel iGlu5 kainate receptor antagonist with neuroprotective effects in global and focal cerebral ischaemia. Neuropharmacology 39 (2000) 1575-1588
132. O'Neill M.J., Bond A., Ornstein P.L., Ward M.A., Hicks C.A., Hoo K., Bleakman D., and Lodge D. Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia. Neuropharmacology 37 (1998) 1211-1222
133. Ornstein P.L., Arnold M.B., Augenstein N.K., Lodge D., Leander J.D., and Schoepp D.D. (3SR,4aRS,6RS, 8aRS)-6-[2-(1H-tetrazol-5-yl)ethyl]-decahydroisoquinoline-3-carboxylic acid: a structurally novel, systemically active, competitive AMPA receptor antagonist. Journal of Medicinal Chemistry 36 (1993) 2046-2048
134. Palecek J., Neugebauer V., Carlton S.M., Iyengar S., and Willis W.D. The effect of a kainate GluR5 receptor antagonist on responses of spinothalamic tract neurons in a model of peripheral neuropathy in primates. Pain 111 (2004) 151-161
135. Palmer M.J., Isaac J.T., and Collingridge G.L. Multiple, developmentally regulated expression mechanisms of long-term potentiation at CA1 synapses. Journal of Neuroscience 24 (2004) 4903-4911
136. Park Y., Jo J., Isaac J.T., and Cho K. Long-term depression of kainate receptor-mediated synaptic transmission. Neuron 49 (2006) 95-106
137. Partin K.M., Patneau D.K., Winters C.A., Mayer M.L., and Buonanno A. Selective modulation of desensitisation at AMPA versus kainate receptors by cyclothiazide and concanavilin A. Neuron 11 (1993) 1069-1082
138. + in the channel gating of native and recombinant kainate receptors. Journal of Neuroscience 23 (2003) 8641-8648
139. Paternain A.V., Morales M., and Lerma J. Selective antagonism of AMPA receptors unmasks kainate receptor-mediated responses in hippocampal neurons. Neuron 14 (1995) 185-189
140. Paternain A.V., Rodríguez-Moreno A., Villarroel A., and Lerma J. Activation and desensitization properties of native and recombinant kainate receptors. Neuropharmacology 37 (1998) 1249-1259
141. Patneau D.K., Mayer M.L., Jane D.E., and Watkins J.C. Activation and desensitization of AMPA/kainate receptors by novel derivatives of willardiine. Journal of Neuroscience 12 (1992) 595-606
142. Pinheiro P., and Mulle C. Kainate receptors. Cell & Tissue Research 326 (2006) 457-482
143. Pickard B.S., Malloy M.P., Christoforou A., Thomson P.A., Evans K.L., Morris S.W., Hampson M., Porteous D.J., Blackwood D.H., and Muir W.J. Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder. Molecular Psychiatry 11 (2006) 847-857
144. Perrais D., Pinheiro P.S., Jane D.E., and Mulle C. Antagonism of recombinant and native GluR7-containing kainate receptors. Neuropharmacology 56 (2009) 131-140
145. Pinheiro P.S., Perrais D., Coussen F., Barhanin J., Bettler B., Mann J.R., Malva J.O., Heinemann S.F., and Mulle C. GluR7 is an essential subunit of presynaptic kainate autoreceptors at hippocampal mossy fiber synapses. Proceedings of the National Academy of Sciences of the United States of America 104 (2007) 12181-12186
146. Plested A.J.R., and Mayer M.L. Structure and mechanism of kainate receptor modulation by anions. Neuron 53 (2007) 829-841
147. Plested A.J.R., Vijayan R., Biggin P.C., and Mayer M.L. Molecular basis of kainate receptor modulation by sodium. Neuron 58 (2008) 720-735
148. Procter M.J., Houghton A.K., Faber E.S., Chizh B.A., Ornstein P.L., Lodge D., and Headley P.M. Actions of kainate and AMPA selective glutamate receptor ligands on nociceptive processing in the spinal cord. Neuropharmacology 37 (1998) 1287-1297
149. Ren Z., Riley N.J., Garcia E.P., Sanders J.M., Swanson G.T., and Marshall J. Multiple trafficking signals regulate kainate receptor KA2 subunit surface expression. Journal of Neuroscience 23 (2003) 6608-6616
150. Rodriguez-Moreno A., Herreras O., and Lerma J. Kainate receptors presynaptically downregulate GABAergic inhibition in the rat hippocampus. Neuron 19 (1997) 893-901
151. Rogawski M.A., Gryder D., Castaneda D., Yonekawa W., Banks M.K., and Li H. GluR5 kainate receptors, seizures and the amygdale. Annals of the New York Academy of Sciences 985 (2003) 150-162
152. Rogawski M.A., Kurzman P.S., Yamaguchi S.I., and Li H. Role of AMPA and GluR5 kainate receptors in the development and expression of amygdale kindling in the mouse. Neuropharmacology 40 (2001) 28-35
153. Sagot E., Pickering D.S., Pu X., Umberti M., Stensbøl T.B., Nielsen B., Chapelet M., Bolte J., Gefflaut T., and Bunch L. Chemo-enzymatic synthesis of a series of 2, 4-syn-functionalised (S)-glutamate analogues: new insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6 and 7. Journal of Medicinal Chemistry 51 (2008) 4093-4103
154. Sakai R., Kamiya H., Murata M., and Shimamoto K. Dysiherbaine: a new neurotoxic amino acid from the Micronesian marine sponge Dysidea herbacea. Journal of the American Chemical Society 119 (1997) 4112-4116
155. Sakai R., Koike T., Sasaki M., Shimamoto K., Oiwa C., Yano A., Suzuki K., Tachibana K., and Kamiya H. Isolation, structure determination, and synthesis of neodysiherbaine A, a new excitatory amino acid from a marine sponge. Organic Letters 3 (2001) 1479-1482
156. Sakai R., Swanson G.T., Shimamoto K., Green T., Contractor A., Ghetti A., Tamura-Horikawa Y., Oiwa C., and Kamiya H. Pharmacological properties of the potent epileptogenic amino acid dysiherbaine, a novel glutamate receptor agonist isolated from the marine sponge Dysidea herbacea. Journal of Pharmacology and Experimental Therapeutics 296 (2001) 650-658
157. Sallert M., Malkki H., SegerstraleTaira T., and Lauri S.E. Effects of the kainate receptor agonist ATPA on glutamatergic synaptic transmission and plasticity during early postnatal development. Neuropharmacology 52 (2007) 1354-1365
158. Sanders J.M., Ito K., Settimo L., Pentikäinen O.T., Shoji M., Sasaki M., Johnson M.S., Sakai R., and Swanson G.T. Divergent pharmacological activity of novel marine-derived excitatory amino acids on glutamate receptors. Journal of Pharmacology and Experimental Therapeutics 314 (2005) 1068-1078
159. Sang C.N., Ramadan N.M., Wallihan R.G., Chappell A.S., Freitag F.G., Smith T.R., Silberstein S.D., Johnson K.W., Phebus L.A., Bleakman D., Ornstein P.L., Arnold B., Tepper S.J., and Vandenhende F. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 24 (2004) 596-602
160. Sasaki M., Maruyama T., Sakai R., and Tachibana K. Synthesis and biological activity of dysiherbaine model compound. Tetrahedron Letters 40 (1999) 3195-3198
161. Schiffer H.H., Swanson G.T., and Heinemann S.F. Rat GluR7 and a carboxy-terminal splice variant, GluR7b, are functional kainate receptor subunits with a low sensitivity to glutamate. Neuron 19 (1997) 1141-1146
162. Schmitz D., Mellor J., Breustedt J., and Nicoll R.A. Presynaptic kainate receptors impart an associative property to hippocampal mossy fiber long-term potentiation. Nature Neuroscience 6 (2003) 1058-1063
163. Schoepp D.D., Lodge D., Bleakman D., Leander J.D., Tizzano J.P., Wright R.A., Palmer A.J., Salhoff C.R., and Ornstein P.L. In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3-carboxylic acid. Neuropharmacology 34 (1995) 1159-1168
164. Scott R., Kullmann D.M., and Rusakov D.A. Cell target specific presynaptic actions of kainate receptors at individual mossy fibre synapses. Proceedings of the Physiological Society 3 (2006) PC168
165. 2+ dynamics at individual mossy fiber-CA3 pyramidal cell synapses. Journal of Neuroscience 26 (2006) 7071-7081
166. Sheardown M.J., Nielsen E.O., Hansen A.J., Jacobsen P., and Honoré T. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science 247 (1990) 571-574
167. Shinozaki H., and Konishi S. Actions of several anthelmintics and insecticides on rat cortical neurones. Brain Research 24 (1970) 368-371
168. Simmons, R.M.A., Katner, J.S., Webster, A.A., Iyengar, S., 2003. Effects of potent, selective GluR5 receptor antagonists in a rodent model of persistent pain. In: 33rd Annual Meeting of the Society for Neuroscience. New Orleans, LA, USA, November 2003 (# 895.9).
169. Simmons R.M.A., Li D.L., Hoo K.H., Deverill M., Ornstein P.L., and Iyengar S. Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat. Neuropharmacology 37 (1998) 25-36
170. Sløk F.A., Ebert B., Lang Y., Krogsgaard-Larsen P., Lenz S., and Madsen U. Excitatory amino-acid receptor agonists. Synthesis and pharmacology of analogues of 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid. European Journal of Medicinal Chemistry 32 (1997) 329-338
171. Small B., Thomas J., Kemp M., Hoo K., Ballyk B., Deverill M., Ogden A.M., Rubio A., Pedregal C., and Bleakman D. LY339434, a GluR5 kainate receptor agonist. Neuropharmacology 37 (1998) 1261-1267
172. K5-containing kainate receptors prevent pilocarpine-induced limbic seizures. Nature Neuroscience 5 (2002) 796-804
173. Strange M., Brauner-Osborne H., and Jensen A.A. Functional characterisation of homomeric ionotropic glutamate receptors GluR1-GluR6 in a fluorescence-based high throughput screening assay. Combinatorial Chemistry & High Throughput Screening 9 (2006) 147-158
174. Strutz N., Villmann C., Thalhammer A., Kizelsztein P., Eisenstein M., Teichberg V.I., and Hollmann M. Identification of domains and amino acids involved in GluR7 ion channel function. Journal of Neuroscience 21 (2001) 401-411
175. Sutton J.L., Maccecchini M.L., and Kajander K.C. The kainate receptor antagonist 2S,4R-4-methylglutamate attenuates mechanical allodynia and thermal hyperalgesia in a rat model of nerve injury. Neuroscience 91 (1999) 283-292
176. Swanson G.T., Green T., and Heinemann S.F. Kainate receptors exhibit differential sensitivities to (S)-5-iodowillardiine. Molecular Pharmacology 53 (1998) 942-949
177. Swanson G.T., Green T., Sakai R., Contractor A., Che W., Kamiya H., and Heinemann S.F. Differential activation of individual subunits in heteromeric kainate receptors. Neuron 34 (2002) 589-598
178. Thomas N.K., Hawkins L.M., Miller J.C., Troop H.M., Roberts P.J., and Jane D.E. Pharmacological differentiation of kainate receptors on neonatal rat spinal motoneurones and dorsal roots. Neuropharmacology 37 (1998) 1223-1237
179. Valgeirsson J., Nielsen E.Ø., Peters D., Mathiesen C., Kristensen A.S., and Madsen U. Bioisosteric modifications of 2-arylureidobenzoic acids: selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5. Journal of Medicinal Chemistry 47 (2004) 6948-6957
180. Valgeirsson J., Nielsen E.Ø., Peters D., Varming T., Mathiesen C., Kristensen A.S., and Madsen U. 2-Arylureidobenzoic acids: selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5. Journal of Medicinal Chemistry 46 (2003) 4383-4386
181. Verdoorn T.A., Johansen T.H., Drejer J., and Nielsen E.Ø. Selective block of recombinant GluR6 receptors by NS-102, a novel non-NMDA receptor antagonist. European Journal of Pharmacology 269 (1994) 43-49
182. Vesikansa A., Sallert M., Taira T., and Lauri S.E. Activation of kainate receptors controls the number of functional glutamatergic synapses in the area CA1 of rat hippocampus. Journal of Physiology 583 (2007) 145-157
183. Vignes M., Bleakman D., Lodge D., and Collingridge G.L. The synaptic activation of the GluR5 subtype of kainate receptor in area CA3 of the rat hippocampus. Neuropharmacology 36 (1997) 1477-1481
184. Vignes M., Clarke V.R., Parry M.J., Bleakman D., Lodge D., Ornstein P.L., and Collingridge G.L. The GluR5 subtype of kainate receptor regulates excitatory synaptic transmission in areas CA1 and CA3 of the rat hippocampus. Neuropharmacology 37 (1998) 1269-1277
185. Vignes M., and Collingridge G.L. The synaptic activation of kainate receptors. Nature 388 (1997) 179-182
186. Vignes M., Mathiesen C., and Collingridge G.L. Activation of a kainate-induced inward current in CA3 hippocampal neurons of immature rats in vitro. Journal of Physiology 495P (1996) 44P
187. Vincent, P., Mulle, C. Kainate receptors in epilepsy and excitotoxicity. Neuroscience, in press, doi:10.1016/j.neuroscience.2008.02.066.
188. Watkins J.C., and Evans R.H. Excitatory amino acid transmitters. Annual Review of Pharmacology and Toxicology 21 (1981) 165-204
189. Watkins J.C., and Jane D.E. The glutamate story. British Journal of Pharmacology 147 (2006) S100-S108
190. Watson G.B., Hood W.F., Monahan J.B., and Lanthorn T.H. Kynurenate antagonizes actions of N-methyl-d-aspartate through a glycine-sensitive receptor. Neuroscience Research Communications 2 (1988) 169-174
191. K5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. Journal of Pharmacology and Experimental Therapeutics 318 (2006) 722-781
192. Wilding T.J., Chai Y.H., and Huettner J.E. Inhibition of rat neuronal kainate receptors by cis-unsaturated fatty acids. Journal of Physiology 532 (1998) 411-421
193. Wilding T.J., and Huettner J.E. Differential antagonism of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring and kainate-preferring receptors by 2,3-benzodiazepines. Molecular Pharmacology 47 (1995) 582-587
194. Wilding T.J., and Huettner J.E. Antagonist pharmacology of kainate- and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring receptors. Molecular Pharmacology 49 (1996) 540-546
195. Wilding T.J., Zhou Y., and Heuttner J.E. Q/R site editing controls kainate receptor inhibition by membrane fatty acids. Journal of Neuroscience 25 (2005) 9470-9478
196. Wilson G.M., Flibotte S., Chopra V., Melnyk B.L., Honer W.G., and Holt R.A. DNA copy-number analysis in bipolar disorder and schizophrenia reveals aberrations in genes involved in glutamate signalling. Human Molecular Genetics 15 (2006) 743-749
197. Woo T.U., Shrestha K., Amstrong C., Minns M.M., Walsh J.P., and Benes F.M. Differential alterations of kainate receptor subunits in inhibitory interneurons in the anterior cingulate cortex in schizophrenia and bipolar disorder. Schizophrenia Research 96 (2007) 46-61
198. Woodward R.M., Huettner J.E., Tran M., Guastella J., Keana J.F.W., and Weber E. Pharmacology of 5-chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinoxalinedione: a novel systemically active ionotropic glutamate receptor antagonist. Journal of Pharmacology and Experimental Therapeutics 275 (1995) 1209-1218
199. Wong A.Y., Fay A.M., and Bowie D. External ions are coactivators of kainate receptors. Journal of Neuroscience 26 (2006) 5750-5755
200. - dipole couples agonist binding to kainate receptor activation. Journal of Neuroscience 27 (2007) 6800-6809
201. Wong L.A., Mayer M.L., Jane D.E., and Watkins J.C. Willardiines differentiate agonist binding sites for kainate-versus AMPA preferring glutamate receptors in DRG and hippocampal neurons. Journal of Neuroscience 14 (1994) 3881-3897
202. Wu L.J., Kim S.S., and Zhou M. Molecular targets of anxiety: from membrane to nucleus. Neurochemistry Research 33 (2008) 1925-1932
203. Wu L.J., Ko S.W., and Zhou M. Kainate receptors and pain; from dorsal root ganglion to the anterior cingulate cortex. Current Pharmaceutical Design 13 (2007) 1597-1605
204. Xu H., Wu L.J., Zhao M.G., Toyoda H., Vadakkan K.I., Jia Y., Pinaud R., and Zhou M. Presynaptic regulation of the inhibitory transmission by GluR5-containing kainate receptors in spinal substantia gelatinosa. Molecular Pain 2 (2006) 29
205. Yue K.T., MacDonald J.F., Pekhletski R., and Hampson D.R. Differential effects of lectins on recombinant glutamate receptors. European Journal of Pharmacology 291 (1995) 229-235
206. Zhou L.-M., Gu Z.-Q., Costa A.M., Yamada K.A., Mansson P.E., Giordano T., Skolnick P., and Jones K.A. (2S,4R)-4-methylglutamic acid (SYM2081): a selective, high-affinity ligand for kainate receptors. Journal of Pharmacology and Experimental Therapeutics 260 (1997) 422-427
207. Zhou N., Hammerland L.G., and Parks T.N. γ-d-glutamylaminomethyl sulfonic acid (GAMS) distinguishes kainic acid- from AMPA-induced responses in Xenopus oocytes expressing chick brain receptors. Neuropharmacology 32 (1993) 767-775